Polyrizon Ltd. (Nasdaq: PLRZ), a development stage biotech company specializing in innovative intranasal hydrogels, has announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs). The studies aim to address the $3.15 billion epilepsy market, focusing on acute repetitive seizures and status epilepticus. Utilizing Polyrizon's proprietary drug delivery platform, the intranasal administration of BZDs is designed to offer rapid, targeted, and patient-friendly seizure rescue therapy. Conducted in collaboration with Professor Fabio Sonvico of the University of Parma, the studies leverage Polyrizon's Trap and Target™ (T&T) platform to enhance the emergency treatment of seizures, providing a faster and more accessible solution for managing acute seizures outside of clinical settings. This initiative marks a significant milestone in improving treatment options for epilepsy patients worldwide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.